Efficacy Study of Cardizem in Pulmonary Arterial Hypertension
Efficacy Study of Cardizem in Pulmonary Arterial Hypertension
The purpose of this study is to determine if cardizem is effective in the treatment of nitric
 oxide non-responder pulmonary arterial hypertension.
Inclusion Criteria:

 -  Adult participants

 -  Confirmed WHO class I pulmonary arterial hypertension

 -  Nitric Oxide Non-Responders on right heart catheterization

 -  Experience dyspnea, NYHA III-IV with poor oxygenation and quality of life despite
 standard treatments

 -  Must be able to swallow medications

 Exclusion Criteria:

 -  Pulmonary hypertension secondary to 1) elevations in pulmonary venous pressures (i.e.
 left heart disease), 2) chronic hypoxemic states from lung diseases such as COPD,
 sleep-disordered breathing, alveolar hypoventilation disorders, chronic exposure to
 high altitude and developmental abnormalities 3) chronic thromboembolic disease, 4)
 sarcoidosis, 5) Lymphangiomyomatosis, 5) Pulmonary Langerhans Cell Histiocytosis

 -  Already on a calcium channel blocker

 -  Systolic blood pressure less than 90

 -  Heart rate less than 55

 -  Pregnant

 -  Cannot sign informed consent

 -  Right heart failure

 -  Pulmonary Veno-occlusive disease